OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - BRISTOL-MYERS SQUIBB | Market Closed - Börse Stuttgart 20:45:17 18/06/2024 BST | ||
| 3.18 EUR | +0.95% |
|
| Current month | +1.60% | ||
| 1 month | +12.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 18/06/24 | 3.18 | +0.95% |
| 17/06/24 | 3.15 | +0.96% |
| 14/06/24 | 3.12 | +0.65% |
| 13/06/24 | 3.1 | +4.03% |
| 12/06/24 | 2.98 | +0.68% |
Delayed Quote Börse Stuttgart
Last update June 18, 2024 at 08:45 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ9QVR |
| ISIN | DE000SQ9QVR6 |
| Date issued | 07/02/2023 |
| Strike | 74.91 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.22 € |
|---|---|
| Lowest since issue | 0.21 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.81
USD
Average target price
53.19
USD
Spread / Average Target
+30.35%
- Stock Market
- Certificates
- Certificat